Welcome to DailyUpdates Neurodegenerative & Neuroelectrophysiological Disorders channel - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 2 more day(s). To receive DailyUpdates by e-mail register here


PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Neurodegenerative & Neuroelectrophysiological Disorders channel



If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work

Today's journal articles

Estrogen receptor alpha gene variants are associated with Alzheimer's disease.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

No clinical trials today

Previous Journal Entries

Design, synthesis and anticholinesterase activity of a novel series of 1 - benzyl - 4 - ((6 - alkoxy - 3 - oxobenzofuran - 2(3H) - ylidene) methyl) pyridinium derivatives.

Discovery and expanded SAR of 4,4 - disubstituted quinazolin - 2 - ones as potent T - type calcium channel antagonists.

Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease.

Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease.

Inhibition of phosphodiesterase-4 reverses memory deficits produced by Abeta25-35 or Abeta1-40 peptide in rats.

S-propargyl-cysteine (ZYZ-802), a sulphur-containing amino acid, attenuates beta-amyloid-induced cognitive deficits and pro-inflammatory response: involvement of ERK1/2 and NF-kappaB pathway in rats.

Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2 - aminopyridine - , and 2 - chloropyridine - 3,5 - dicarbonitriles.

Controlling Amyloid-beta Peptide(1-42) Oligomerization and Toxicity by Fluorinated Nanoparticles.

In vitro ADMET and physicochemical investigations of poly - N - methylated peptides designed to inhibit Abeta aggregation.

New halogenated 3 - phenylcoumarins as potent and selective MAO - B inhibitors.

Hit - to - lead optimization of a series of carboxamides of ethyl 2 - amino - 4 - phenylthiazole - 5 - carboxylates as novel adenosine A(2A) receptor antagonists.

Effect of VEGF and its receptor antagonist SU-5416, an inhibitor of angiogenesis, on processing of the beta-amyloid precursor protein in primary neuronal cells derived from brain tissue of Tg2576 mice.

Neuropsychological rehabilitation in adult multiple sclerosis.

Endothelin-A receptor antagonist BQ123 potentiates acetaminophen induced hypothermia and reduces infarction following focal cerebral ischemia in rats.

Discovery of novel alpha7 nicotinic receptor antagonists.

An orally bioavailable positive allosteric modulator of the mGlu(4) receptor with efficacy in an animal model of motor dysfunction.

Neuroprotective properties of PGI 2 IP receptor in focal cerebral ischemia.

Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: A prospective, nonrandomized, open-label, uncontrolled, observational pilot study.

The H(3) Antagonist, Ciproxifan, Alleviates the Memory Impairment but Enhances the Motor Effects of MK-801 (Dizocilpine) in Rats.

Intensification of long-term memory deficit by chronic stress and prevention by nicotine in a rat model of Alzheimer's disease.

Today's News Items

No news items selected today

Training Courses & Meetings

No events listed

Previous News Items

GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine

Teriflunomide Significantly Reduced Annualized Relapse Rate and was well Tolerated in MS patients